Recent NICE guidance recommends nintedanib as an option for treating idiopathic pulmonary fibrosis, only if: the person has FVC between 50% and 80% of predicted; the company provides it with the discount agreed in the patient access scheme and treatment is stopped if disease progresses (a confirmed decline in percent predicted FVC of ≥10%) in any 12-month period.